vs
INVESTORS TITLE CO（ITIC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是INVESTORS TITLE CO的1.8倍（$127.1M vs $69.5M），再鼎医药同比增速更快（17.1% vs -1.6%），INVESTORS TITLE CO自由现金流更多（$25.4M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 14.0%）
该公司是全球首家产权保险公司，前身为费城房地产产权保险公司，目前专注于为房地产交易提供产权保险相关服务，保障房地产交易中产权方的合法权益，在产权保险领域拥有悠久的发展历史与行业积累。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ITIC vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.8倍
$69.5M
营收增速更快
ZLAB
高出18.7%
-1.6%
自由现金流更多
ITIC
多$52.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
14.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $69.5M | $127.1M |
| 净利润 | — | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 13.8% | -54.6% |
| 净利率 | — | — |
| 营收同比 | -1.6% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $3.97 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ITICZLAB
| Q4 25 | $69.5M | $127.1M | ||
| Q3 25 | $73.0M | $115.4M | ||
| Q2 25 | $73.6M | $109.1M | ||
| Q1 25 | $56.6M | $105.7M | ||
| Q4 24 | $70.6M | $108.5M | ||
| Q3 24 | $68.8M | $101.8M | ||
| Q2 24 | $65.4M | $100.1M | ||
| Q1 24 | $53.5M | $87.1M |
净利润ITICZLAB
| Q4 25 | — | — | ||
| Q3 25 | $12.2M | $-36.0M | ||
| Q2 25 | $12.3M | $-40.7M | ||
| Q1 25 | $3.2M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.3M | $-41.7M | ||
| Q2 24 | $8.9M | $-80.3M | ||
| Q1 24 | $4.5M | $-53.5M |
毛利率ITICZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率ITICZLAB
| Q4 25 | 13.8% | -54.6% | ||
| Q3 25 | 20.7% | -42.3% | ||
| Q2 25 | 21.5% | -50.3% | ||
| Q1 25 | 7.2% | -53.3% | ||
| Q4 24 | 15.3% | -62.6% | ||
| Q3 24 | 16.8% | -66.6% | ||
| Q2 24 | 17.2% | -76.0% | ||
| Q1 24 | 10.8% | -80.7% |
净利率ITICZLAB
| Q4 25 | — | — | ||
| Q3 25 | 16.7% | -31.2% | ||
| Q2 25 | 16.7% | -37.3% | ||
| Q1 25 | 5.6% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.5% | -40.9% | ||
| Q2 24 | 13.6% | -80.2% | ||
| Q1 24 | 8.5% | -61.4% |
每股收益（稀释后）ITICZLAB
| Q4 25 | $3.97 | $-0.05 | ||
| Q3 25 | $6.45 | $-0.03 | ||
| Q2 25 | $6.48 | $-0.04 | ||
| Q1 25 | $1.67 | $-0.04 | ||
| Q4 24 | $4.41 | $-0.09 | ||
| Q3 24 | $4.92 | $-0.04 | ||
| Q2 24 | $4.70 | $-0.08 | ||
| Q1 24 | $2.40 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.6M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $268.3M | $715.5M |
| 总资产 | $363.1M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ITICZLAB
| Q4 25 | $89.6M | $689.6M | ||
| Q3 25 | $110.8M | $717.2M | ||
| Q2 25 | $90.1M | $732.2M | ||
| Q1 25 | $81.7M | $757.3M | ||
| Q4 24 | $83.8M | $779.7M | ||
| Q3 24 | $112.9M | $616.1M | ||
| Q2 24 | $111.2M | $630.0M | ||
| Q1 24 | $135.0M | $650.8M |
股东权益ITICZLAB
| Q4 25 | $268.3M | $715.5M | ||
| Q3 25 | $278.0M | $759.9M | ||
| Q2 25 | $266.2M | $791.7M | ||
| Q1 25 | $254.4M | $810.8M | ||
| Q4 24 | $251.8M | $840.9M | ||
| Q3 24 | $271.3M | $667.7M | ||
| Q2 24 | $261.8M | $704.2M | ||
| Q1 24 | $254.0M | $762.2M |
总资产ITICZLAB
| Q4 25 | $363.1M | $1.2B | ||
| Q3 25 | $363.3M | $1.2B | ||
| Q2 25 | $345.8M | $1.2B | ||
| Q1 25 | $333.8M | $1.2B | ||
| Q4 24 | $333.6M | $1.2B | ||
| Q3 24 | $352.0M | $985.3M | ||
| Q2 24 | $340.3M | $987.4M | ||
| Q1 24 | $329.5M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.9M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $25.4M | $-26.7M |
| 自由现金流率自由现金流/营收 | 36.5% | -21.0% |
| 资本支出强度资本支出/营收 | 8.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $47.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ITICZLAB
| Q4 25 | $30.9M | $-26.0M | ||
| Q3 25 | $17.2M | $-32.0M | ||
| Q2 25 | $8.9M | $-31.0M | ||
| Q1 25 | $-75.0K | $-61.7M | ||
| Q4 24 | $29.8M | $-55.8M | ||
| Q3 24 | $7.8M | $-26.8M | ||
| Q2 24 | $8.4M | $-42.2M | ||
| Q1 24 | $1.4M | $-90.1M |
自由现金流ITICZLAB
| Q4 25 | $25.4M | $-26.7M | ||
| Q3 25 | $15.8M | $-35.0M | ||
| Q2 25 | $7.3M | $-33.9M | ||
| Q1 25 | $-1.4M | $-63.2M | ||
| Q4 24 | $22.4M | $-58.4M | ||
| Q3 24 | $6.1M | $-28.2M | ||
| Q2 24 | $6.3M | $-42.9M | ||
| Q1 24 | $-793.0K | $-91.1M |
自由现金流率ITICZLAB
| Q4 25 | 36.5% | -21.0% | ||
| Q3 25 | 21.7% | -30.4% | ||
| Q2 25 | 9.9% | -31.1% | ||
| Q1 25 | -2.5% | -59.9% | ||
| Q4 24 | 31.7% | -53.8% | ||
| Q3 24 | 8.8% | -27.7% | ||
| Q2 24 | 9.7% | -42.9% | ||
| Q1 24 | -1.5% | -104.5% |
资本支出强度ITICZLAB
| Q4 25 | 8.0% | 0.5% | ||
| Q3 25 | 1.8% | 2.6% | ||
| Q2 25 | 2.1% | 2.6% | ||
| Q1 25 | 2.4% | 1.5% | ||
| Q4 24 | 10.5% | 2.4% | ||
| Q3 24 | 2.5% | 1.3% | ||
| Q2 24 | 3.2% | 0.7% | ||
| Q1 24 | 4.2% | 1.1% |
现金转化率ITICZLAB
| Q4 25 | — | — | ||
| Q3 25 | 1.40× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | -0.02× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.95× | — | ||
| Q1 24 | 0.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ITIC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
